BHCM
TARS icon

Brevan Howard Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Brevan Howard Capital Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$503K Buy
+7,993
New +$511K ﹤0.01% 1444
2026
Q1 		– Sell
-4,458
Closed -$365K – 2479
2025
Q4 		$365K Sell
4,458
-17,969
-80% -$1.34M ﹤0.01% 1263
2025
Q3 		$1.33M Buy
+22,427
New +$1.1M 0.01% 770
2024
Q4 		– Sell
-43,380
Closed -$1.43M – 1419
2024
Q3 		$1.43M Buy
+43,380
New +$1.22M 0.01% 343

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Brevan Howard Capital Management's TARS Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in Tarsus Pharmaceuticals (TARS) in Q2 2026: 7,993 shares worth $503K. The stake represents ﹤0.01% of the portfolio and ranks #1444 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in TARS as recently as Q4 2025.

Brevan Howard Capital Management first reported a position in TARS in Q3 2024 and has held it in 4 quarters since. The position peaked at $1.43M in Q3 2024. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Brevan Howard Capital Management held 7,993 shares of Tarsus Pharmaceuticals worth $503K as of Q2 2026.
  • Tarsus Pharmaceuticals was a new Brevan Howard Capital Management position in Q2 2026.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1444 holding.
  • Brevan Howard Capital Management first reported a position in Tarsus Pharmaceuticals in Q3 2024 and has held it in 4 quarters since.
  • Brevan Howard Capital Management's Tarsus Pharmaceuticals position peaked at $1.43M in Q3 2024.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.